Post-Workshop Evaluation Form

Post-Workshop Questionnaire
Beyond the Scoop: Interpreting and Communicating
Trial Results for New HIV Prevention Technologies
Please complete this questionnaire after the workshop. It should take you no longer than 15
minutes to complete.
Your feedback will help us evaluate the workshop and inform future planning to advance our
work on new prevention technologies. Your responses will be anonymous and confidential.
1. In order for us to match your pre-assessment and
post-assessment, please provide us with the same
code word that you used before the workshop.
CODE WORD:
______________________________
2. Which perspective(s) are you representing? (please check all that apply)
Person living with HIV or AIDS
Advocate
Researcher
Policy maker
Health Care Provider
Student
Service Provider
Educator
Other (please specify):
3. What are the 3 most important “take-home messages” that you heard during the
Workshop?
a)
b)
c)
Knowledge Test
4. Microbicides could be designed to protect against:
a) HIV
b) STIs
c) Pregnancy
d) All of the above
1

5. _______________ can be defined as administering medications used in the treatment of
HIV to "high risk" HIV-negative individuals in hopes of preventing transmission of the virus.
a) Proactive Highly Active Antiretroviral Treatment
b) Post Exposure Prophylaxis
c) Pre Exposure Prophylaxis
d) Harm Reduction
6. All of the following would make a drug a good candidate for Pre Exposure Prophylaxis
EXCEPT:
a) Easy to use: Only one pill required per day (maybe less).
b) Safe: Few side effects in HIV-positive people.
c) Sedative: Makes a person sleepy so they don’t engage in risky behaviours
d) Powerful: Stays in the bloodstream a long time.
e) Unique resistance profiles: If resistance develops, other treatment options still exist.
7. A vaccine works by:
a) teaching the body to recognize an infectious agent
b) laying dormant, then attacking an infectious agent once it invades the body
c) helping the body remain healthy despite an infection (keeps it in check)
d) layering cells in protective armour
8. Clinical trials are:
a) A process of testing products in humans
b) A process of testing products in animals
c) A process of testing products in the laboratory
d) A process of administering products in clinics
9. “Informed consent” in clinical trials is:
a) A group education process that includes signing an agreement with other potential
volunteers in the trial
b) The continuous process of explaining to volunteers all information about a clinical trial
or study to ensure that they understand and independently sign an agreement before
joining
c) The process of informing a participant about a trial
d) The consent given by volunteers to receive information about a specific issue
2

10. Effectiveness of an NPT refers to:
a) The cost of producing the NPT compared to the profit from the NPT
b) The ability of a NPT to reduce incidence of the disease in the community
c) The ability of a NPT to produce an immune response against the disease
d) The ability of a NPT to produce an immune response in the shortest time possible
11. Efficacy of a NPT refers to:
a) The ability of the NPT to prevent infection or disease in the trial population
b) The ability of the NPT to protect against diseases other than the one it was intended for
c) The ability of the NPT to protect against the disease 100% of the time
d) The ability of the NPT to produce quick results
12. Randomisation in clinical trials is:
a) A process of choosing at random which participants will get the candidate product or
the placebo
b) A random process of choosing countries where the NPT trial is going to be conducted
c) A random process of selecting people from the population to be part of the NPT trial
d) When a participant makes a choice to belong to either the placebo group or the
candidate product group
13. A placebo is:
a) A place where the NPT is being tested in animals
b) A substance that is given to volunteers to reduce potential side effects
c) A harmless, inactive substance that resembles the candidate product in appearance
d) A chemical substance used to determine when someone was infected by HIV
14. The main objective of a Phase I clinical trial is to find out if the candidate product:
a) Is safe
b) Causes an immune response
c) Protects against infection or disease
d) Causes disease
15. The main objective of Phase III clinical trial is to find out if the candidate product:
a) Is safe
b) Provokes an immune response
c) Protects against infection or disease
d) Causes disease
3

16. What was your favourite part of the workshop?
What was the least enjoyable / valuable part of the workshop?
17.
Please indicate your agreement
with the following statements:
This Workshop provided me with new insights
about new HIV prevention technologies.
Participating in this Workshop was a good use
of my time.
I will be able to apply the content of this
Workshop to my everyday work.
I made new contacts which will be helpful in
my everyday work or everyday life.
Strongly
Agree
Please circle one
Agree Neutral Disagree
Strongly
Disagree
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
Overall, the facilitation style was effective. 5 4 3 2 1
There was adequate time allocated for
informal discussions among workshop
participants.
5 4 3 2 1
The Workshop was well-organized. 5 4 3 2 1
18. What changes would you recommend to make this Workshop better?
19. Any other comments?
Thank you very much for completing this questionnaire,
and thanks for your participation in the Workshop.
4